Patients with inclusion body myositis will have to continue to wait for an effective treatment since the latest randomised controlled trial of a potential therapy failed to impress. The phase 2b RESILIENT study of bimagrumab versus placebo found no improvement in the primary outcome of six-minute walk distance (6MWD) or secondary outcomes including isometric muscle ...
Myositis awaits effective treatment after negative results with bimagrumab
By Mardi Chapman
19 Aug 2019